PureTech Health PLC

NASDAQ PRTC

Data sourced from

and

Daily

Download Data

PureTech Health PLC Market Capitalization on June 03, 2024: USD 838.28 M

PureTech Health PLC Market Capitalization is USD 838.28 M on June 03, 2024, a 10.74% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

PureTech Health PLC 52-week high Market Capitalization is USD 891.82 M on May 31, 2024, which is 6.39% above the current Market Capitalization.
PureTech Health PLC 52-week low Market Capitalization is USD 461.76 M on December 07, 2023, which is -44.92% below the current Market Capitalization.
PureTech Health PLC average Market Capitalization for the last 52 weeks is USD 679.67 M.

NASDAQ: PRTC

PureTech Health PLC

CEO	Ms. Daphne Zohar
IPO Date	Nov. 16, 2020
Location	United States
Headquarters	6 Tide Street, Boston, MA, United States, 02210
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends